Microbiome Drug Developer Raises $50m For First-In-Human Studies

PureTech Health business Vedanta Biosciences Inc. – a company developing a new class of therapies designed to modulate the human microbiome – has raised $50m through new equity investments to advance several of its programs into the clinic.

Vedanta, founded by PureTech with technology from the laboratory of scientific co-founder Dr. Kenya Honda, will use this latest influx of cash to conduct serval trials of its novel drugs based on live commensal microbes in infectious and autoimmune disease indications. Vedanta will also use some of the funds to scale up its technology platform.

The company has previously been funded by seed investment from PureTech and upfront and milestone payments related to a deal...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip